➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Boehringer Ingelheim
Harvard Business School
Baxter
Express Scripts

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

EYSUVIS Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Eysuvis, and what generic alternatives are available?

Eysuvis is a drug marketed by Kala Pharms Inc and is included in one NDA. There are eleven patents protecting this drug.

This drug has seventy patent family members in twelve countries.

The generic ingredient in EYSUVIS is loteprednol etabonate. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.

Summary for EYSUVIS
International Patents:70
US Patents:11
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for EYSUVIS
What excipients (inactive ingredients) are in EYSUVIS?EYSUVIS excipients list
DailyMed Link:EYSUVIS at DailyMed
Drug patent expirations by year for EYSUVIS
Drug Prices for EYSUVIS

See drug prices for EYSUVIS

US Patents and Regulatory Information for EYSUVIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kala Pharms Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Kala Pharms Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Kala Pharms Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Kala Pharms Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Kala Pharms Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Kala Pharms Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Kala Pharms Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Harvard Business School
Baxter
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.